Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study

NCT03464201 is registered in ClinicalTrials.gov with Grupo Español de Tumores Huérfanos e Infrecuentes as lead sponsor.

NCT NCT03464201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03464201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study
Lead sponsor
Grupo Español de Tumores Huérfanos e Infrecuentes
Phase
Phase 2
Overall status
Completed
Start date
April 13, 2018
Completion date
November 11, 2020
Enrollment
16 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer